Shots:

• The P-III ENSEMBLE trial to evaluate the efficacy and safety of Janssen’s COVID-19 vaccine candidate in protecting mod-to-severe COVID-19 in 43-783 participants accruing 468 symptomatic cases with assessment of efficacy as of day 14 and as of day 28 as co-primary endpoints
• Results: The level of protection against mod-to-severe COVID-19 infection was 72% in the US- 66% in Latin America- 57% in South Africa; 28 days post-vaccination and 85% effective in preventing severe disease and complete protection & death as of day 28
• The company plans to provide affordable COVID-19 vaccine at a not-for-profit basis for emergency pandemic use- pending regulatory authorizations

 ­ Ref: Johnson & Johnson | Image: Johnson & Johnson